Effectiveness of Monovalent mRNA Vaccines Against Omicron XBB Infection in Singaporean Children Younger Than 5 Years
JAMA Pediatrics · 2023
DOI: 10.1001/jamapediatrics.2023.4505 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Pediatrics, 2023. Verfasst von Liang En Wee und 9 weiteren Autor:innen. Beteiligte Einrichtung: National Centre for Infectious Diseases, Singapore. Hauptthemen laut MEDLINE: COVID-19 Vaccines, COVID-19. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Importance Literature on vaccine effectiveness of SARS-CoV-2 messenger RNA (mRNA) vaccines for children younger than 5 years is limited.
Objective
To report the effectiveness of monovalent mRNA vaccines against SARS-CoV-2 infection among Singaporean children aged 1 through 4 years during a COVID-19 pandemic wave of the Omicron XBB variant. Design, Setting, and Participants This was a population-based cohort study, conducted over a 6-month study period from October 1, 2022, through March 31, 2023, after the implementation of community vaccination among all Singaporean children aged 1 through 4 years. The study period was dominated by the Omicron XBB subvariant. Exposure Receipt of SARS-CoV-2 mRNA vaccines. Main Outcome Measure Vaccine effectiveness against confirmed SARS-CoV-2 infection. The adjusted incidence rate ratio for confirmed infections using Poisson regression was reported, with the reference group being those who were unvaccinated. Analyses were stratified by prior documented SARS-CoV-2 infection.
Results
A total of 121 628 children (median [IQR] age, 3.1 [2.2-3.9] years; 61 925 male [50.9%]) were included in the study, contributing 21 015 956 person-days of observation. The majority of children (11 294 of 11 705 [96.5%]) received the mRNA-1273 COVID-19 vaccine (Moderna). Vaccine effectiveness against confirmed infection was 45.2% (95% CI, 24.7%-60.2%) in partially vaccinated, infection-naive children and 63.3% (95% CI, 40.6%-77.3%) in fully vaccinated, infection-naive children compared with the unvaccinated group. Among previously infected children, vaccine effectiveness against reinfections in those with at least 1 vaccine dose was estimated at 74.6% (95% CI, 38.7%-89.5%). Conclusions and Relevance Study results suggest that completion of a primary mRNA vaccine series provided protection against SARS-CoV-2 infection in children aged 1 through 4 years. Although incidence of hospitalization and severe illness is low in this age group, there is potential benefit of vaccination in preventing infection and potential sequelae.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- National Centre for Infectious Diseases, Singapore.
- Duke-NUS Graduate Medical School, National University of Singapore, Singapore.
- Department of Infectious Diseases, Singapore General Hospital, Singapore.
- Ministry of Health, Singapore.
- Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.
- Infectious Disease Service, Department of Paediatrics, KK Women's and Children's Hospital, Singapore.
Zitieren
APA
Wee, L. E., Tang, N., Pang, D., Chiew, C., Yung, C. F., Chong, C. Y., Lee, V., Ong, B., Lye, D. C., & Tan, K. B. (2023). Effectiveness of Monovalent mRNA Vaccines Against Omicron XBB Infection in Singaporean Children Younger Than 5 Years. JAMA Pediatrics. https://doi.org/10.1001/jamapediatrics.2023.4505
Vancouver
Wee LE, Tang N, Pang D, Chiew C, Yung CF, Chong CY, et al. Effectiveness of Monovalent mRNA Vaccines Against Omicron XBB Infection in Singaporean Children Younger Than 5 Years. JAMA Pediatrics. 2023. doi:10.1001/jamapediatrics.2023.4505
BibTeX
@article{Wee2023,
author = {Wee, Liang En and Tang, Nicole and Pang, Deanette and Chiew, Calvin and Yung, Chee-Fu and Chong, Chia Yin and Lee, Vernon and Ong, Benjamin and Lye, David Chien and Tan, Kelvin Bryan},
title = {Effectiveness of Monovalent mRNA Vaccines Against Omicron XBB Infection in Singaporean Children Younger Than 5 Years},
journal = {JAMA Pediatrics},
year = {2023},
doi = {10.1001/jamapediatrics.2023.4505}
}
EUVIMED